Mar 05, 2018 8:00 am EST CymaBay Therapeutics to Participate in Upcoming Investor Conferences in March
Feb 01, 2018 4:01 pm EST CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jan 08, 2018 8:00 am EST Enrollment Begins in Long-Term Extension Study of Seladelpar in Patients with Primary Biliary Cholangitis
Jan 08, 2018 8:00 am EST CymaBay Therapeutics Receives $5 Million Milestone Payment for Arhalofenate from Kowa Pharmaceuticals America
Jan 02, 2018 4:01 pm EST CymaBay Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
Dec 04, 2017 8:00 am EST CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel